Exagen’s Chernett lifts stake 2.7% but plans to disgorge short-swing profit (NASDAQ: XGN)

What happened

Jorey Chernett, a 10% owner of Exagen Inc. (NASDAQ: XGN), bought 71,315 shares on Nov. 11. The purchase lifts Chernett's direct holding to 2,696,940 shares.

The Form 4 reports a weighted average price of $5.23 a share, about $373,000 in total. Chernett bought in multiple transactions at prices from $4.82 to $5.42.

The form also says the reported transactions are matchable under Section 16(b) of the Securities Exchange Act of 1934. Chernett has calculated a short-swing profit and intends to disgorge it to Exagen.

Key numbers

Metric	Latest	Change	Source
Shares bought	71,315 shares		SEC Form 4
Weighted average price	$5.23		SEC Form 4
Total cost	about $373,000		SEC Form 4
Holding after purchase	2,696,940 shares		SEC Form 4
Purchase as share of prior holding	2.7%		Calculated from SEC Form 4

Read more: Exagen (XGN) company research

Why it matters

The purchase equals 2.7% of the 2,625,625 shares Chernett held before the trade, by OptimistFi's calculation. It is a modest addition to an already large position.

OptimistFi has argued that Exagen must keep winning rheumatology adoption for AVISE while protecting reimbursement and gross margin until the company can fund itself. A 10% owner adding shares is consistent with that view, but the purchase leaves the investment case unchanged.

The short-swing language limits what the trade says. Because Chernett intends to disgorge a profit on these matchable transactions, the buy is a weaker signal of long-term conviction than a clean purchase would be.

The disgorgement also changes who benefits. Chernett has already calculated the short-swing profit on the matchable transactions and intends to pay it to Exagen, so the company, not the holder, receives that amount.

The price spread matters for reading the filing. Because the shares were bought in multiple transactions across a range of prices, the form reports a weighted average rather than a single execution price. Investors should treat that average as a summary of the buying, not as the level of any one trade.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Exagen's next quarterly report is the next test of the case. Stronger AVISE adoption with stable reimbursement and gross margin would support the owner's added stake, while weaker readings on those measures would undercut it.

More from OptimistFi

• XGN stock: research and coverage of Exagen
• Stock research on every company OptimistFi covers

From OptimistFi Perps